Cover Image
Market Research Report

Global Herpes Zoster Treatment Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 745579
Published Content info 102 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Herpes Zoster Treatment Market 2019-2023
Published: November 8, 2018 Content info: 102 Pages
Description

About this market

With the emerging innovative vaccines for disease management, there is a growing demand for herpes zoster treatment drugs. Until the development of vaccines, the treatment for herpes zoster was dependent completely on drug therapies. However, vendors have been focusing on developing several new therapies for the treatment and prevention of shingles. For instance, in October 2017, Shingrix was launched by GlaxoSmithKline for the treatment of shingles. The vaccine is much more effective than ZOSTAVAX, which was the only approved vaccine for shingles in older adults. Technavio's analysts have predicted that the herpes zoster treatment market will register a CAGR of almost 14% by 2023.

Market Overview

Rising incidence of herpes zoster

Factors such as exposure to ultraviolet radiation may suppress the cell-mediated immunity, which can be a major factor responsible for the growing incidence of herpes zoster. Patients being treated for cancer and affected with advanced HIV infection are at a greater risk of developing shingles, which is expected to boost the growth of the global herpes zoster treatment market.

Weak pipeline for herpes zoster

The number of herpes zoster pipeline agents are very limited despite the growing incidence of the infection worldwide, which is likely to hamper the growth of the global herpes zoster treatment market.

For the detailed list of factors that will drive and challenge the growth of the herpes zoster treatment market during the 2019-2023 period, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Abbott and GlaxoSmithKline, the competitive environment is quite intense. Factors such as the emerging innovative vaccines for disease management and rising incidence of herpes zoster, will provide considerable growth opportunities to herpes zoster treatment companies. Abbott, GlaxoSmithKline, Merck, and Novartis are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR30133

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Vaccination - Market size and forecast 2018-2023
  • Drug therapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Abbott
  • GlaxoSmithKline
  • Merck
  • Novartis

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

PART 16: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global infectious disease treatment market
  • Exhibit 02: Segments of global infectious disease treatment market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline molecules for the treatment of herpes zoster
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Vaccination - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Vaccination - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Drug therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Drug therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Key leading countries
  • Exhibit 35: Market opportunity
  • Exhibit 36: Impact of drivers and challenges
  • Exhibit 37: Vendor landscape
  • Exhibit 38: Landscape disruption
  • Exhibit 39: Vendors covered
  • Exhibit 40: Vendor classification
  • Exhibit 41: Market positioning of vendors
  • Exhibit 42: Abbott - Vendor overview
  • Exhibit 43: Abbott - Business segments
  • Exhibit 44: Abbott - Organizational developments
  • Exhibit 45: Abbott - Geographic focus
  • Exhibit 46: Abbott - Segment focus
  • Exhibit 47: Abbott - Key offerings
  • Exhibit 48: GlaxoSmithKline - Vendor overview
  • Exhibit 49: GlaxoSmithKline - Business segments
  • Exhibit 50: GlaxoSmithKline - Organizational developments
  • Exhibit 51: GlaxoSmithKline - Geographic focus
  • Exhibit 52: GlaxoSmithKline - Segment focus
  • Exhibit 53: GlaxoSmithKline - Key offerings
  • Exhibit 54: Merck - Vendor overview
  • Exhibit 55: Merck - Business segments
  • Exhibit 56: Merck - Organizational developments
  • Exhibit 57: Merck - Geographic focus
  • Exhibit 58: Merck - Key offerings
  • Exhibit 59: Novartis - Vendor overview
  • Exhibit 60: Novartis - Business segments
  • Exhibit 61: Novartis - Organizational developments
  • Exhibit 62: Novartis - Geographic focus
  • Exhibit 63: Novartis - Segment focus
  • Exhibit 64: Novartis - Key offerings
Back to Top